Cooperative Agreement U24CA224020

The National Cancer Institute (NCI), under the Cancer Biology Research Program (CFDA 93.396), awarded a $654,197 Project Grant to The General Hospital Corporation (doing business as Massachusetts General Hospital) for a research project titled "Pancreatic Cancer Patient-Derived Xenograft Tumors for Translational Studies in Precision Cancer Medicine". The project aims to employ a unique collection of molecularly annotated low-passage patient-derived xenograft (PDX) tumors, spatial...

Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $739,640 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded September 1, 2025, with completion targeted for August 31, 2030. The project, "Developing Methods for Advancing the Early Detection of Pancreatic Ductal Adenocarcinoma Leveraging Electronic Medical Records Data," focuses on developing and validating innovative early...

The National Cancer Institute awarded a $1.28 million Cooperative Agreement to The Leland Stanford Junior University under the Cancer Biology Research program (CFDA 93.396) on July 25, 2025, with completion targeted for May 31, 2030. This award supports fundamental research investigating the molecular determinants of metastatic ability, organ tropism, and immune evasion in pancreatic ductal adenocarcinoma (PDAC). The research integrates genetic barcoding with single-cell profiling...

This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...

Cooperative Agreement Summary The National Cancer Institute awarded a $2.05M Cooperative Agreement to Massachusetts General Hospital under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025 through August 31, 2028. The award supports the development and optimization of novel CAR-T (chimeric antigen receptor T cell) therapies targeting pancreatic cancer. The research deliverables include the advancement of meso-FAP CAR-TEAM cells—engineered T cells that...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $109,080 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cancer Research Manpower program (CFDA 93.398) to conduct a Phase II, investigator-initiated, multicenter randomized controlled trial (RCT) evaluating novel immunotherapeutic approaches for treatment-naive metastatic pancreatic ductal adenocarcinoma (MPDA). The award, effective September 1, 2025, through...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $402,401.00 to Emory University to develop a PET CCR2 imaging agent to profile the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC). The project aims to advance diagnostic and profiling capabilities for this highly aggressive cancer, which is the 4th leading cause of cancer-related death. The award has a period of performance from July 4, 2024 to...

Federal Cooperative Agreement Award Summary The University of Florida, in partnership with AdventHealth, received an $858,331 cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through June 30, 2030. This award supports the Chronic Pancreatitis Clinical Research Consortium (CPCRC), which continues research from the...

This $667,118 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The project will focus on studying the role of key lysosomal factors, including PLBD1 and LGMN, that are essential for the survival and growth of pancreatic ductal...

Federal Cooperative Agreement Award Summary The Beckman Research Institute of the City of Hope received a $690,637 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) beginning September 1, 2025, and concluding August 31, 2030. The award supports the development and validation of a blood-based biomarker test for early detection of pancreatic ductal adenocarcinoma (PDAC) that leverages 5-methylcytosine (5MC) and...